J3M-MC-JZQB
Study for patients with KRAS G12C-Mutant Metastatic Non-Small Cell Lung Cancer
Developer: Medable Inc.
App Size: Varies With Device
Release Date: Jul 2, 2024
Price: Free
Medical
J3M-MC-JZQB
Screenshots for App
Mobile
A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression (TPS ≥ 50%). This app is specifically intended for participants in the J3M-MC-JZQB study only.
J3M-MC-JZQB 5.4.900.2-prod Update
2025-09-04 Version History
Bug fixes and performance improvements.
~Medable Inc.
~Medable Inc.
More Information about: J3M-MC-JZQB
Price:
Free
Version:
5.4.900.2-prod
Downloads:
42
Compatibility:
Android 8.0
Bundle Id:
com.medable.lilly.jzqb
Size:
Varies With Device
Last Update:
2025-09-04
Content Rating:
Everyone
Release Date:
Jul 2, 2024
Content Rating:
Everyone
Developer:
Medable Inc.
Latest Apps & Games
